Quick Takeaways
- Bain Capital Life Sciences Opportunities III, LP filed SCHEDULE 13G/A for KYVERNA THERAPEUTICS, INC. Common Stock, $0.00001 par value per share (KYTX).
- Disclosed ownership: 5.4%.
- Date of event: 31 Dec 2025.
Bain Capital Life Sciences Opportunities III, LP - 31 Dec 2025 SCHEDULE 13G/A Report for KYVERNA THERAPEUTICS, INC. Common Stock, $0.00001 par value per share (KYTX)
- Filing Manager
- Bain Capital Life Sciences Opportunities III, LP
- Reporting Manager
- Bain Capital Life Sciences Opportunities III, LP
- Symbol
- KYTX
- Shares outstanding
- 57,592,593 shares
- Disclosed Ownership
- 3,110,000 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:30:03 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Bain Capital Life Sciences Opportunities III, LP disclosed 5.4% ownership in KYVERNA THERAPEUTICS, INC. Common Stock, $0.00001 par value per share (KYTX) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Opportunities III, LP | 5.4% | 3,110,000 | 0 | 3,110,000 | /s/ Adam Koppel | Adam Koppel, Partner of Bain Capital Life Sciences Investors, LLC |